Results · Apr-Jun 2026 · filed 3 Aug 2026
GlaxoSmithkline Pharmaceuticals Q1 FY27 results
Sales grew 17% to ₹938 crore from ₹805 crore in Apr-Jun 2025.
Operating profit grew 18% to ₹296 crore, an operating margin of 31.5% (up 0.3 points from a year ago).
Net profit grew 16% to ₹237 crore from ₹205 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −6%, net profit −15%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 938.4 | 805.2 | +17% |
| Operating profit (EBITDA) | 295.5 | 251.2 | +18% |
| Operating margin | 31.5% | 31.2% | +0.3 pts |
| Net profit | 237.2 | 205.0 | +16% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 6 Aug 2026Disclosure Under Regulation 30
- 5 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 4 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 3 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 3 Aug 2026Announcement under Regulation 30 (LODR)-Change in Management
- 3 Aug 2026Announcement under Regulation 30 (LODR)-Resignation of Director
- 3 Aug 2026Announcement under Regulation 30 (LODR)-Change in Directorate
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.